# Let's talk about it: the fifty answers > The checked answers Nori, an AI, speaks from in Let's talk about it, a voice conversation about weight, fat and GLP-1 medicines at glp.mobeus.com, built by Mobeus. Prices and coverage are as of September 2026 and change often. Not medical advice. Velunori is a fictional sample medicine. ## Is it cheating to use a GLP-1? Not in any medical sense. Cheating means breaking a rule, and there is no rule that weight must come off by effort alone. Weight is shaped by genes and by hunger hormones that push back after weight loss. The Wegovy, Zepbound and Foundayo labels add the medicine to eating less and moving more, rather than replacing them. Whether one suits you, and when, is yours to work out with a clinician. The worry is common, and research links it to beliefs about willpower. In 2025 studies of 640 US adults, people who saw weight as mostly willpower were more likely to call these medicines an unfair easy way out. In the main trials of semaglutide, sold as Wegovy, and tirzepatide, sold as Zepbound, everyone also got diet and activity counseling. Placebo groups lost about 2 to 3 percent, versus about 15 percent on semaglutide and 21 percent on tirzepatide's top dose, in separate maker-funded trials. Side effects are real too. Sources: - Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet 2022;23(2):120-133 (online Sep 2021). doi:10.1038/s41576-021-00414-z (https://pmc.ncbi.nlm.nih.gov/articles/PMC8459824/) - Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med 2011;365:1597-1604 (https://www.nejm.org/doi/full/10.1056/NEJMoa1105816) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Goldkorn M, Schwartz B, Monterosso J. Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower. Obes Sci Pract 2025;11(2):e70041 (two online studies, N=640 total) (https://pmc.ncbi.nlm.nih.gov/articles/PMC12012989/) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - AMA Policy H-440.842, Recognition of Obesity as a Disease (adopted June 2013, Resolution 420 A-13) (https://policysearch.ama-assn.org/policyfinder/detail/H-440.842?uri=/AMADoc/HOD.xml-0-3858.xml) - Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x (endorsing organizations listed as of Feb 26, 2020) (https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/) - Rubino F, et al. Definition and diagnostic criteria of clinical obesity (Lancet Diabetes & Endocrinology Commission). Lancet Diabetes Endocrinol 2025;13:221-262. Publisher page blocked (HTTP 403); details checked via Pennington Biomedical Research Center summary (https://www.pbrc.edu/news/media/2025/lancetcommission.aspx) and Europe PMC index (PMID 39824205) (https://doi.org/10.1016/S2213-8587(24)00316-4) ## Why does it feel like nobody talks about this openly? Partly because people fear judgment, and early research suggests that fear has a basis. In a late-2025 KFF poll, 12 percent of US adults, about 1 in 8, said they were taking a GLP-1. Yet 2026 online experiments found people judged someone more harshly for losing weight with one than through diet and exercise, often seeing it as a shortcut. So feeling torn about sharing is common, and understandable. Those experiments used fictional people, so they show attitudes, not how anyone actually behaves. The harsher judgment tracked beliefs about willpower and shortcuts, not anything about the person taking the medicine. Weight stigma reaches well beyond these medicines. A 2020 international consensus reported that 19 to 42 percent of adults with obesity face weight discrimination. I haven't found solid numbers on how many people keep their GLP-1 use private. Sources: - Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (fielded Oct 27-Nov 2, 2025; n=1,350; affordability and prescription-source figures are among adults who have ever taken a GLP-1 drug) (https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/) - Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. Int J Obes 2026;50(7):1478-1485 (online Apr 3, 2026). doi:10.1038/s41366-026-02061-y (https://pmc.ncbi.nlm.nih.gov/articles/PMC13391369/) - Post SM, Stock ML, Persky S. Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity. Stigma and Health 2026. doi:10.1037/sah0000689 (https://pmc.ncbi.nlm.nih.gov/articles/PMC13196875/) - Goldkorn M, Schwartz B, Monterosso J. Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower. Obes Sci Pract 2025;11(2):e70041 (two online studies, N=640 total) (https://pmc.ncbi.nlm.nih.gov/articles/PMC12012989/) - Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x (endorsing organizations listed as of Feb 26, 2020) (https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/) ## Do I have to tell people I'm taking one? No. It's your health information, and who hears about it is your call. Some people tell only a partner or one close friend, some tell everyone, and some just say they're working with their doctor on their health. The ones who do need to know are your prescribers, your pharmacist and anyone sedating you for a procedure, even at the dentist. These medicines slow the stomach, which matters for other pills and for sedation. People often think about who will be supportive rather than full of opinions, who shares meals with them and will notice smaller portions, and who could help if side effects got bad, like a partner. At work, many people keep it simple, like saying they're eating smaller portions these days. If side effects start affecting your job, a clinician can help you decide what to tell an employer. Being careful about who you tell is understandable, not dishonest. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. Int J Obes 2026;50(7):1478-1485 (online Apr 3, 2026). doi:10.1038/s41366-026-02061-y (https://pmc.ncbi.nlm.nih.gov/articles/PMC13391369/) - Post SM, Stock ML, Persky S. Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity. Stigma and Health 2026. doi:10.1037/sah0000689 (https://pmc.ncbi.nlm.nih.gov/articles/PMC13196875/) ## Am I lazy if I need a medicine for my weight? Laziness doesn't explain it. A 2020 international consensus of experts said the belief that weight comes mainly from a lack of self-discipline doesn't fit the scientific evidence. It also called it unacceptable that many health professionals see people with obesity as lazy. After weight loss, the body often pushes back through hunger hormones and a slower metabolism. Needing help with that biology says nothing bad about you. If you've called yourself lazy, you're not alone. A 2018 study estimated that about 40 to 50 percent of US adults with overweight or obesity turn weight stigma on themselves. One small study followed 14 TV weight-loss contestants for six years. On average, their resting metabolism was still about 704 calories a day lower than at the start, even after regaining most of the weight. Another found the hunger hormone ghrelin still higher, and fullness hormones lower, a year after a diet. Sources: - Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x (endorsing organizations listed as of Feb 26, 2020) (https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/) - Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med 2011;365:1597-1604 (https://www.nejm.org/doi/full/10.1056/NEJMoa1105816) - Fothergill E, et al. Persistent metabolic adaptation 6 years after "The Biggest Loser" competition. Obesity 2016;24(8):1612-1619 (https://onlinelibrary.wiley.com/doi/full/10.1002/oby.21538) ## Is wanting to lose weight a good enough reason? Wanting it is a fine reason to ask. Whether it's a reason to prescribe depends on your health. The labels cover adults with obesity, or with overweight plus a weight-related condition such as high blood pressure. A clinician will look at your BMI and your wider health, and may say yes, not yet, or suggest something else. Any of those is part of a fair conversation. A 2025 Lancet commission argued BMI alone shouldn't diagnose obesity. It split clinical obesity, where excess fat is already affecting how the body works, from preclinical obesity, where risk is raised but organs still work normally. Not every expert accepts those definitions. If disordered eating is part of your story, say so. A 2025 advisory calls a restrictive eating disorder a general reason not to use these medicines, and being open about it keeps you safe. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - FDA Approves New Medication for Chronic Weight Management (Zepbound, tirzepatide) (https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management) - Rubino F, et al. Definition and diagnostic criteria of clinical obesity (Lancet Diabetes & Endocrinology Commission). Lancet Diabetes Endocrinol 2025;13:221-262. Publisher page blocked (HTTP 403); details checked via Pennington Biomedical Research Center summary (https://www.pbrc.edu/news/media/2025/lancetcommission.aspx) and Europe PMC index (PMID 39824205) (https://doi.org/10.1016/S2213-8587(24)00316-4) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## What is a GLP-1, in plain words? GLP-1 is a hormone your own gut makes after you eat. It helps your pancreas release insulin when blood sugar rises, lowers glucagon, slows how fast your stomach empties, and reduces how much people eat. GLP-1 medicines, like semaglutide in Wegovy or tirzepatide in Zepbound, are lab-made molecules that switch on the same receptor and last far longer than the natural hormone. Your own GLP-1 is gone from the blood in about one to two minutes, so early researchers had to give it as a constant drip. The history of these medicines is largely about making the molecule last. Semaglutide lasts about a week, which is why its shot is weekly. Tirzepatide also switches on a second gut-hormone receptor, called GIP. Orforglipron, the medicine in the Foundayo pill, is a small chemical molecule rather than a peptide, yet it still switches on the GLP-1 receptor. Scientists don't yet understand every pathway. Sources: - Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008 (abstract via Europe PMC, PMID 18640588) (https://doi.org/10.1016/s1262-3636(08)73397-4) - Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci USA 2024 (https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## What is food noise, and why does it go quiet? Food noise is an everyday phrase, not a diagnosis. Researchers describe it as persistent, unwanted thoughts about food that feel intrusive. Many people on GLP-1 medicines say it goes quiet, possibly because these medicines act on brain areas tied to appetite and reward. The evidence is early, though. Tools to measure it only date from 2025, and I found no completed randomized trial with food noise as its main outcome. In a 2026 survey of 550 US adults on semaglutide injections, the median food-noise score fell from 13 to 6 out of 20. That survey was funded by Novo Nordisk, had no comparison group, and asked people to remember how things were before. In a small brain-recording study, one woman taking tirzepatide found her food thoughts went quiet at first, then came back after about five months. One person can't tell us what happens to most people. Sources: - Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutr Diabetes 2025;15:30 (abstract via Europe PMC, PMID 40628707) (https://doi.org/10.1038/s41387-025-00382-x) - Hayashi D, et al. What Is Food Noise? A Conceptual Model of Food Cue Reactivity. Nutrients 2023;15(22):4809 (https://doi.org/10.3390/nu15224809) - Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity 2025;33(2):289-297 (abstract via Europe PMC, PMID 39828656) (https://doi.org/10.1002/oby.24216) - Retrospective Assessment of Food Noise Changes After Initiation of Injectable Semaglutide for Weight Management in the USA: The INFORM Survey. Adv Ther 2026 (funded by Novo Nordisk) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13415491/) - Her food cravings vanished on Mounjaro then roared back (news summary of a University of Pennsylvania Nature Medicine study with implanted brain electrodes in four people with obesity and loss-of-control eating, focused on one participant; secondary source) (https://www.sciencedaily.com/releases/2025/12/251208052534.htm) - van Bloemendaal L, et al. GLP-1 receptor activation modulates appetite- and reward-related brain areas in humans. Diabetes 2014 (abstract via Europe PMC, PMID 25071023) (https://doi.org/10.2337/db14-0849) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) ## How are semaglutide and tirzepatide different? The main difference is how many gut-hormone signals they act on. Semaglutide, the medicine in Novo Nordisk's Wegovy and Ozempic, switches on one receptor, GLP-1. Tirzepatide, in Eli Lilly's Zepbound and Mounjaro, switches on two, GIP and GLP-1. Both are weekly shots, and semaglutide has a pill form as well. Tirzepatide averaged more weight loss when the two went head to head in a trial Lilly paid for, but averages don't predict one person's result. What GIP adds in people isn't settled. The Zepbound label says only that nonclinical studies suggest it may add to appetite control. That head-to-head trial, SURMOUNT-5, was open-label and measured weight and waist, not heart attacks or strokes. The two molecules also last different lengths of time in the body, about a week for semaglutide and about 5 days for tirzepatide, which is why both are taken once a week. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - Ozempic (semaglutide) injection, US Prescribing Information (revised 05/2026) (https://www.novo-pi.com/ozempic.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - Mounjaro (tirzepatide) injection, US Prescribing Information with Boxed Warning (revised 08/2026) (https://pi.lilly.com/us/mounjaro-uspi.pdf) - Gautier JF, Choukem SP, Girard J. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. Diabetes Metab 2008 (abstract via Europe PMC, PMID 18640588) (https://doi.org/10.1016/s1262-3636(08)73397-4) - Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2416394) - Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389(24). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2307563) - Lam CSP et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring) 2025;33(9):1645-1656. doi:10.1002/oby.24332 (https://pubmed.ncbi.nlm.nih.gov/40545827/) ## What do people mean by a newer generation of GLP-1? It's an informal way of talking, not an official category. People usually mean the timeline. Exenatide, approved in 2005, lasts only a few hours in the body. Liraglutide became a daily shot, semaglutide a weekly one, and tirzepatide added a second hormone. Now there are pills, including orforglipron, which isn't a peptide at all. Newer doesn't automatically mean better for any one person. Next-wave candidates, like Lilly's retatrutide and Novo Nordisk's CagriSema, aren't approved. Exenatide was modelled on a peptide found in Gila monster venom, and it lasts about 2.4 hours. Liraglutide stretched that to about 13 hours, and semaglutide to about a week. The next wave works on more signals at once. Retatrutide acts on three receptors, while CagriSema and amycretin also mimic amylin, a pancreas hormone that adds to fullness. As of September 2026 none of them is approved, and anything sold online as retatrutide is not an approved medicine. Sources: - Drugs@FDA original (ORIG-1) approval records for Byetta, Victoza, Saxenda, Ozempic, Rybelsus, Wegovy, Wegovy tablets, Mounjaro, Zepbound and Foundayo, and the NDA 213051 product list (Rybelsus and Ozempic semaglutide tablets), queried through the openFDA drugsfda API (https://www.accessdata.fda.gov/scripts/cder/daf/) - Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci USA 2024 (https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline) (https://www.prnewswire.com/news-releases/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss-in-pivotal-phase-3-obesity-trial-302778859.html) - Novo Nordisk files for FDA approval of CagriSema, the first once-weekly combination of GLP-1 and amylin analogues for weight management (https://www.prnewswire.com/news-releases/novo-nordisk-files-for-fda-approval-of-cagrisema-the-first-once-weekly-combination-of-glp1-and-amylin-analogues-for-weight-management-302645862.html) - Novo Nordisk's subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025 (https://www.globenewswire.com/news-release/2025/06/20/3102977/0/en/novo-nordisk-s-subcutaneous-and-oral-amycretin-data-published-in-the-lancet-and-presented-at-ada-2025.html) - Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obes Metab (abstract via Europe PMC, PMID 41090431) (https://doi.org/10.1111/dom.70209) - Volčanšek Š, et al. Amylin: From Mode of Action to Future Clinical Potential in Diabetes and Obesity. Diabetes Ther 2025 (https://doi.org/10.1007/s13300-025-01733-8) - Dahl K, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. Lancet 2025 (abstract via Europe PMC) (https://doi.org/10.1016/S0140-6736(25)01185-7) ## Is a pill as good as a shot? The pills work, but neither was tested directly against a shot in the trials behind its approval. The Wegovy pill, oral semaglutide at 25 milligrams, averaged 13.6 percent weight loss at 64 weeks. The Wegovy shot averaged 14.9 percent at 68 weeks in its own trial. Foundayo, which is orforglipron, averaged 11.2 percent at its top dose over 72 weeks. Separate trials in different people aren't a direct comparison. The two pills work differently. Only about 1 to 2 percent of the semaglutide in the Wegovy pill reaches the blood, so it needs an empty stomach, a little water and a 30-minute wait. In people without diabetes, blood levels on the 25 milligram pill were similar to the 2.4 milligram shot. About 77 percent of orforglipron reaches the blood, and it can be taken with or without food, but some other medicines can change its levels. Sources: - Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med 2025;393(11):1077-1087. Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2500969) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2511774) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## How do Wegovy and Zepbound compare? Both are weekly shots approved for weight in adults, but they differ. Wegovy, semaglutide from Novo Nordisk, also comes as a daily pill and is approved to lower heart attack and stroke risk in people with heart disease. Zepbound, tirzepatide from Eli Lilly, acts on two gut-hormone signals and is approved for sleep apnea with obesity. In an open-label head-to-head trial funded by Lilly, Zepbound averaged more weight loss. In that trial, SURMOUNT-5, average loss at 72 weeks was 20.2 percent on tirzepatide and 13.7 percent on semaglutide, tested only up to 2.4 milligrams, not the newer 7.2 milligram Wegovy HD. Wegovy has a heart-outcome trial in people without diabetes. A similar tirzepatide trial hasn't reported yet. Both carry a boxed warning about thyroid tumors. As of September 2026, self-pay was $349 a month for Wegovy 2.4 milligrams, and $449 for Zepbound's higher doses with refills within 45 days, or up to $699 without. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2416394) - Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389(24). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2307563) - Lam CSP et al. Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT-MMO trial. Obesity (Silver Spring) 2025;33(9):1645-1656. doi:10.1002/oby.24332 (https://pubmed.ncbi.nlm.nih.gov/40545827/) - Wegovy (semaglutide) Savings, Self Pay, & Home Delivery, NovoCare Pharmacy (https://www.novocare.com/pharmacy/wegovy/offer.html) - Authentic Zepbound (tirzepatide) Shipped to You, LillyDirect product and self-pay price page (CMAT-05333 08/2026) (https://www.lilly.com/lillydirect/zepbound) ## Are Ozempic and Mounjaro the same as Wegovy and Zepbound? Same medicines, different approved uses. Ozempic and Wegovy both contain semaglutide from Novo Nordisk. Mounjaro and Zepbound both contain tirzepatide from Eli Lilly. Ozempic and Mounjaro are approved for type 2 diabetes, not for weight management. Wegovy and Zepbound are the weight brands. Doses can differ too, and the labels advise against using them together. The brand on a prescription can also change what insurance covers. Ozempic goes up to 2 milligrams a week, while Wegovy goes to 2.4 or 7.2. Mounjaro and Zepbound come in the same six strengths. The Ozempic pill, a reformulation of the Rybelsus tablets, has been on sale in the US since May 2026 for type 2 diabetes. The Wegovy pill is the weight version. Regular Medicare drug plans may pay for them for diabetes, but not for weight loss alone. A temporary Medicare program, the GLP-1 Bridge, covers some weight brands for people who qualify. Sources: - Ozempic (semaglutide) injection, US Prescribing Information (revised 05/2026) (https://www.novo-pi.com/ozempic.pdf) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - Mounjaro (tirzepatide) injection, US Prescribing Information with Boxed Warning (revised 08/2026) (https://pi.lilly.com/us/mounjaro-uspi.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US (https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html) - What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge (updated May 11, 2026) (https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Medicare GLP-1 Bridge: Information for Providers (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers) ## What are the new GLP-1 pills? Two GLP-1 pills are approved for weight in the US. The Wegovy pill is oral semaglutide from Novo Nordisk, taken each morning on an empty stomach with a little water, then a 30-minute wait before eating. Foundayo is orforglipron from Eli Lilly, a small-molecule pill taken once a day, with or without food. As of September 2026, self-pay prices for both started at $149 a month. Both start low and step up after 30 days or more on each dose. The Wegovy pill goes from 1.5 up to 25 milligrams. Foundayo goes from 0.8 up to as high as 17.2. Foundayo is broken down by a liver enzyme, so some other medicines change its levels. The Ozempic pill is also semaglutide, but it's for type 2 diabetes, not weight. Both weight pills carry a boxed warning about thyroid C-cell tumors. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Drugs@FDA original (ORIG-1) approval records for Byetta, Victoza, Saxenda, Ozempic, Rybelsus, Wegovy, Wegovy tablets, Mounjaro, Zepbound and Foundayo, and the NDA 213051 product list (Rybelsus and Ozempic semaglutide tablets), queried through the openFDA drugsfda API (https://www.accessdata.fda.gov/scripts/cder/daf/) - FDA approves first oral GLP-1 treatment for type 2 diabetes (FDA news release, reposted on PR Newswire; the fda.gov page now returns 404) (https://www.prnewswire.com/news-releases/fda-approves-first-oral-glp-1-treatment-for-type-2-diabetes-300922431.html) - Novo Nordisk's Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US (https://www.prnewswire.com/news-releases/novo-nordisks-ozempic-pill-the-only-fda-approved-oral-peptide-glp-1-medication-for-adults-with-type-2-diabetes-soon-to-be-available-in-the-us-302760106.html) - FDA approves Lilly's Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions (https://www.prnewswire.com/news-releases/fda-approves-lillys-foundayo-orforglipron-the-only-glp-1-pill-for-weight-loss-that-can-be-taken-any-time-of-day-without-food-or-water-restrictions-302731485.html) - Wegovy (semaglutide) Savings, Self Pay, & Home Delivery, NovoCare Pharmacy (https://www.novocare.com/pharmacy/wegovy/offer.html) - Authentic Foundayo (orforglipron) Shipped to You, LillyDirect product and self-pay price page (CMAT-19155 09/2026) (https://www.lilly.com/lillydirect/foundayo) - Foundayo coverage and savings page with Savings Card and Self-Pay terms and conditions (card expires 12/31/2026) (https://foundayo.lilly.com/coverage-savings) ## How long have these medicines been around? GLP-1 medicines have been used in the US since 2005, when exenatide, sold as Byetta, was approved for type 2 diabetes. Weight approvals came later: liraglutide as Saxenda in 2014, semaglutide as Wegovy in 2021, tirzepatide as Zepbound in 2023, and orforglipron as Foundayo in 2026. The science goes back to 1982. The newest weight options, the two pills and Wegovy HD, have the shortest track records. The research started long before the medicines. In 1982, researchers studying the anglerfish glucagon gene found it also coded for a glucagon-like peptide. By 1987, a short form of GLP-1 had been found in the gut and shown to trigger insulin release from rat pancreas. In 2024, three GLP-1 pioneers received the Lasker Award. Weight-dose trials in people without diabetes are much younger, and that's where most of the open questions sit. Sources: - Drugs@FDA original (ORIG-1) approval records for Byetta, Victoza, Saxenda, Ozempic, Rybelsus, Wegovy, Wegovy tablets, Mounjaro, Zepbound and Foundayo, and the NDA 213051 product list (Rybelsus and Ozempic semaglutide tablets), queried through the openFDA drugsfda API (https://www.accessdata.fda.gov/scripts/cder/daf/) - 2024 Lasker~DeBakey Clinical Medical Research Award: GLP-1-based therapy for obesity (Habener, Mojsov, Knudsen) (https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/) - Friedman JM. The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity. Proc Natl Acad Sci USA 2024 (https://pmc.ncbi.nlm.nih.gov/articles/PMC11441540/) - FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide (https://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide) - Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389(24). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2307563) - Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024 (https://doi.org/10.1038/s41591-024-02996-7) ## What is Velunori, and why is it here? Velunori is a fictional sample medicine. It isn't real, no one can prescribe it, and it has no approval, trials or safety data. It's here to illustrate how a medicine can be explained through conversation, without pointing at any real brand. When you ask about real medicines, like Wegovy, Zepbound or Foundayo, I use public sources and I'm designed not to favour any of them. A made-up example lets the site show how answers, cards and short explainers can work, without it reading like an advert for a real product. Anything said about Velunori is illustration only. It has no real price, coverage or label. If you've wondered whether you could get it, you can't. A clinician can talk with you about the real options. ## Who are these medicines approved for? In the US, Wegovy, Zepbound and Foundayo are approved for adults with obesity, or with overweight plus at least one weight-related health problem. In the trials, that meant a BMI of 30 or more, or 27 or more with a condition like high blood pressure. The Wegovy injection also covers teens 12 and up with obesity. Ozempic and Mounjaro use the same medicines, semaglutide and tirzepatide, but they're diabetes brands. A few have extra uses. The Wegovy injection and the Wegovy pill are also approved to lower heart attack and stroke risk in adults with heart disease and obesity or overweight. The Wegovy injection has an accelerated approval for MASH, a liver disease, when there's moderate to advanced scarring but not cirrhosis. Zepbound, the tirzepatide shot, is approved for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo, the orforglipron pill, is approved for weight only. Every label expects diet and activity changes alongside it. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Ozempic (semaglutide) injection, US Prescribing Information (revised 05/2026) (https://www.novo-pi.com/ozempic.pdf) - Mounjaro (tirzepatide) injection, US Prescribing Information with Boxed Warning (revised 08/2026) (https://pi.lilly.com/us/mounjaro-uspi.pdf) - FDA Approves New Medication for Chronic Weight Management (Zepbound, tirzepatide) (https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management) - Deputy Division Director Summary Review, NDA 215256 Wegovy (action date June 4, 2021) (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215256Orig1s000SumR.pdf) - FDA approves once-weekly semaglutide for adolescents with obesity (secondary source; cites Novo Nordisk's December 23, 2022 announcement) (https://www.healio.com/news/endocrinology/20230103/fda-approves-onceweekly-semaglutide-for-adolescents-with-obesity) - FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or) - FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound) (https://www.fda.gov/news-events/press-announcements/fda-approves-first-medication-obstructive-sleep-apnea) - Wegovy approved by FDA for the treatment of adults with noncirrhotic MASH with moderate to advanced liver fibrosis (https://www.prnewswire.com/news-releases/wegovy-approved-by-fda-for-the-treatment-of-adults-with-noncirrhotic-mash-with-moderate-to-advanced-liver-fibrosis-302531394.html) ## How do I know if I'm ready? There's no test for it. It mostly comes down to whether this fits your life for the long haul, since weight often returns after stopping. People weigh paying for it month after month, and riding out some nausea or constipation while the dose climbs. Knowing your own reason, and having a clinician you can be honest with, matter too. Feeling unsure is a normal place to start. It helps to think in years, not months, because trial participants who came off these medicines typically saw much of the weight return within a year. In KFF polling from late 2025, 56% of people who had taken a GLP-1 said it was difficult to afford, and 14% had stopped because of cost. It's worth telling a clinician about your other medicines, pregnancy plans and any history of disordered eating. A not yet from them is a normal answer, not a rejection. Sources: - Choosing a Safe & Successful Weight-loss Program (last reviewed Feb 2024) (https://www.niddk.nih.gov/health-information/weight-management/choosing-a-safe-successful-weight-loss-program) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (fielded Oct 27-Nov 2, 2025; n=1,350; affordability and prescription-source figures are among adults who have ever taken a GLP-1 drug) (https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/) - Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564 (https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/) - Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48 (online Dec 11, 2023). Abstract verified via Europe PMC (https://doi.org/10.1001/jama.2023.24945) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## Who should not take a GLP-1? The Wegovy, Zepbound and Foundayo labels rule out three groups: people with a personal or family history of medullary thyroid cancer, people with a syndrome called MEN 2, and anyone who's had a serious allergic reaction to the medicine. The thyroid rule ties to a boxed warning about tumors seen in rodent studies. None is recommended with severe gastroparesis, and for weight use, each says to stop once pregnancy is known. There are brand differences too. Foundayo isn't recommended with severe liver impairment or while breastfeeding, and breastfeeding isn't recommended on the Wegovy pill. Among these, only the Wegovy injection is approved for teens. No label recommends taking two GLP-1 medicines together. A 2025 advisory from four obesity and nutrition groups asks clinicians to screen for eating disorders first, and calls a restrictive eating disorder a general contraindication. None of this is a judgment about you. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## What if I want to get pregnant someday? Wanting a baby later mostly means planning the timing. For weight use, every label says to stop once pregnancy is recognized. The Wegovy label says to stop at least two months before trying, because semaglutide lingers in the body. The Zepbound and Foundayo labels set no window, so that's a clinician conversation. And in some people, especially with PCOS, ovulation can return as weight comes down, raising the chance of an unplanned pregnancy. Birth control needs a look too. Zepbound can make birth control pills less reliable, so its label advises a non-pill method or adding condoms for 4 weeks after starting and after each dose increase. Foundayo's label says the same for 30 days and advises effective contraception throughout. Patches, rings, implants, shots and hormonal IUDs shouldn't be affected. If pregnancy happens during treatment, the labels say to stop, so call your clinician and ask about a pregnancy registry. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Almaradweh S, Mousa E. Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists. Cureus 2026;18(7):e111915 (narrative review; secondary source) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13428985/) ## I take other medicines. Does that change things? Often, yes. These medicines slow the stomach, which can change how other pills are absorbed. With insulin or a sulfonylurea, low blood sugar becomes more likely, so those doses may need adjusting. Zepbound and Foundayo can make birth control pills less reliable for a while. Foundayo also interacts with certain drugs, like the antibiotic clarithromycin and the statin simvastatin. Share your full list, supplements included, with your prescriber and pharmacist. The labels add some specifics. In a study, semaglutide tablets raised levels of levothyroxine, a thyroid medicine, by 33%, so it's worth mentioning if you take it. Zepbound has low potential for liver-enzyme interactions, but its label advises monitoring pills with a narrow safety margin, such as warfarin. Foundayo is capped at 9 milligrams with strong CYP3A4 blockers, and simvastatin should stay at 20 milligrams a day or less. No label recommends combining two GLP-1 medicines, like Wegovy with Ozempic or Zepbound with Mounjaro. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## How much weight do people really lose? Counting everyone who started, trial averages ran from about 11% to 21% of body weight over 64 to 72 weeks. Foundayo, or orforglipron, averaged about 11% on its top dose. Semaglutide averaged about 14 to 15% as the Wegovy pill or weekly shot, and about 19% as Wegovy HD. Zepbound, or tirzepatide, averaged about 21% on its top dose. Placebo groups lost 2 to 4%. These were separate trials, not a ranking. A few cautions. Some headlines quote the bigger if-everyone-stayed-on number instead of the count-everyone one. People with type 2 diabetes tended to lose less. When the two were compared directly in SURMOUNT-5, which Lilly paid for and ran open-label, tirzepatide averaged 20.2% and semaglutide 13.7% over 72 weeks. Semaglutide topped out at 2.4 milligrams there. Real-world results usually come in lower, largely because many people stop early. Sources: - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. Abstract via PubMed (PMID 40961952) (https://doi.org/10.1016/S2213-8587(25)00226-8) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med 2025;393(11):1077-1087. Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2500969) - Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. doi:10.1056/NEJMoa2511774 (https://pubmed.ncbi.nlm.nih.gov/40960239/) - Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity (ATTAIN-1 topline, both estimands) (https://www.prnewswire.com/news-releases/lillys-oral-glp-1--orforglipron-delivers-weight-loss-of-up-to-an-average-of-27-3-lbs-in-first-of-two-pivotal-phase-3-trials-in-adults-with-obesity-302523649.html) - FDA approves Novo Nordisk's Wegovy pill, the first and only oral GLP-1 for weight loss in adults (https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only-oral-glp-1-for-weight-loss-in-adults-302648344.html) - Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2416394) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Dziewierz A, Siudak Z. Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support. A Narrative Review. Nutrients 2026;18(11). Abstract via Europe PMC (https://doi.org/10.3390/nu18111761) ## How fast does it work? Gradually, over months rather than weeks. Each of these medicines starts at a low dose and steps up about once a month at the fastest, and the Wegovy shot doesn't reach its usual dose until week 17. The headline averages were measured at 64 to 72 weeks, and loss often kept going for many months. The first weeks are mostly about getting used to it. Two trials show how loss continued. In STEP 4, people who stayed on Wegovy lost a further 7.9% between weeks 20 and 68. In SURMOUNT-4, people who stayed on tirzepatide, sold as Zepbound, lost a further 5.5% between weeks 36 and 88. Both only included people who got through the early months. The Wegovy pill reaches its top 25 milligram dose on day 91. When to judge progress is worth agreeing with your clinician at the start. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. doi:10.1001/jama.2023.24945 (https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). N Engl J Med 2025;393(11):1077-1087. Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2500969) - Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. Abstract via PubMed (PMID 40961952) (https://doi.org/10.1016/S2213-8587(25)00226-8) - Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. doi:10.1056/NEJMoa2511774 (https://pubmed.ncbi.nlm.nih.gov/40960239/) ## Will I get the average result? Maybe, maybe not. An average sits in the middle of a wide spread. On semaglutide 2.4 milligrams, sold as Wegovy, 66% lost at least 10% and about 3 in 10 lost 20% or more. On tirzepatide, sold as Zepbound, 57% on the top dose lost 20% or more, yet 9 to 15% across doses lost under 5%. These were separate trials. Nobody can predict one person's result, me included. Outside trials, results usually run lower, mostly because plenty of people stop early. Inside them, higher doses generally brought more loss, and people living with type 2 diabetes lost less on average. It's fairer to measure progress against your own starting point than against a headline, and a clinician can help you do that. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. doi:10.1056/NEJMoa2511774 (https://pubmed.ncbi.nlm.nih.gov/40960239/) - Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025. Abstract via PubMed (PMID 40961952) (https://doi.org/10.1016/S2213-8587(25)00226-8) - Dziewierz A, Siudak Z. Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support. A Narrative Review. Nutrients 2026;18(11). Abstract via Europe PMC (https://doi.org/10.3390/nu18111761) ## What is the first month like? It starts slow on purpose. Each of these medicines begins at a low dose for about four weeks, so your body can adjust before it goes up. The stomach is where people notice it most: nausea, feeling full sooner, diarrhea or constipation. For most it's mild to moderate and eases with time. Smaller meals, going easy on fatty food, and sipping fluids tend to help. The Wegovy pill has strict morning rules: empty stomach, up to half a cup of water, and a 30-minute gap before food or other pills. Foundayo can be taken any time, with or without food. On Zepbound or Foundayo, birth control pills may be less reliable for the first four weeks or 30 days, so a backup method matters. If you can't keep fluids down, call your clinician, because losing too much fluid can harm the kidneys. Severe belly pain that may spread to your back needs urgent care. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## What happens if I stop? Usually, much of the weight comes back. A year after stopping semaglutide, sold as Wegovy, people in one study had regained about two-thirds of what they lost. In a trial of tirzepatide, sold as Zepbound, people switched to placebo regained 14% of body weight within a year, ending about 10% below their start. Blood pressure and other markers drift back too. That's biology, not failure. A 2026 BMJ review of 37 studies found weight returned faster after stopping medicines than after diet programs, about 0.8 kilograms a month for semaglutide and tirzepatide, projecting a return to starting weight in about a year and a half. Tapering and planned breaks haven't been well tested. If you're weighing stopping, for cost, side effects or anything else, plan it with your prescriber. After two missed Wegovy shots in a row, or seven Foundayo pills, the labels say to restart lower. Zepbound's label leaves it to the prescriber. Sources: - Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564 (https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/) - Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. doi:10.1001/jama.2023.24945 (https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/) - Aronne LJ, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48 (online Dec 11, 2023). Abstract verified via Europe PMC (https://doi.org/10.1001/jama.2023.24945) - West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 2026 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## What are the common side effects? Mostly stomach trouble. Nausea, diarrhea, vomiting and constipation lead the list for semaglutide (Wegovy), tirzepatide (Zepbound) and orforglipron (Foundayo). In the main weight trials, nausea hit 28 to 44% of people at the higher doses, versus 8 to 16% on placebo. These effects are most common while the dose is going up, and they usually ease with time. Headache, tiredness and some hair loss show up too. Most are mild to moderate. Side effects led about 5 to 10% of people on these medicines to stop, versus about 3% on placebo. Doses go up in steps, about every four weeks, partly to give your gut time to adjust. Smaller meals may help, and in the first days fatty or high-fiber foods can make nausea worse. Vomiting or diarrhea that won't stop can dry you out and strain the kidneys, so that's a reason to call your prescriber rather than wait. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## What is the thyroid cancer warning about? It comes from animal studies. Semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) caused thyroid C-cell tumors in rodents, and no one knows yet whether that happens in people. So those brands and Foundayo all carry a boxed warning, the FDA's strongest kind. Human studies so far disagree. Anyone with a personal or family history of medullary thyroid carcinoma, or MEN 2 syndrome, must not take them. Foundayo is a special case. Orforglipron doesn't act on the rat or mouse receptor and didn't cause these tumors, but its label keeps the warning because the human relevance is unknown. A study of 145,410 users in Denmark, Norway and Sweden found no substantial rise over an average of 3.9 years. A French study in people with type 2 diabetes linked one to three years of use to higher risk. Tell a clinician about a lump in your neck, lasting hoarseness, or trouble swallowing or breathing. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - Ozempic (semaglutide) injection, US Prescribing Information (revised 05/2026) (https://www.novo-pi.com/ozempic.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - Mounjaro (tirzepatide) injection, US Prescribing Information with Boxed Warning (revised 08/2026) (https://pi.lilly.com/us/mounjaro-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Bezin J, et al. GLP-1 Receptor Agonists and the Risk of Thyroid Cancer. Diabetes Care 2023 (abstract via Europe PMC, PMID 36356111) (https://doi.org/10.2337/dc22-1148) - Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 2024 (https://doi.org/10.1136/bmj-2023-078225) ## What are the rare but serious risks? Beyond the boxed thyroid warning, the Wegovy, Zepbound and Foundayo labels warn about pancreatitis, gallbladder disease and kidney injury. Pancreatitis is rare but can be severe. Gallstones show up more than on placebo. Heavy vomiting or diarrhea can dry you out and hurt the kidneys. The labels also list serious allergic reactions, severe stomach problems including bowel blockage, and food getting into the lungs under anesthesia. These are uncommon. Confirmed pancreatitis was 4 people on Wegovy versus 1 on placebo, 0.2% on both Zepbound and placebo, and 6 people on Foundayo versus 1. Gallstones ran about 1 to 2.5% on the medicines, versus 0.7 to 1% on placebo. One records study linked semaglutide or liraglutide to more gastroparesis, but lasting stomach paralysis after stopping hasn't been shown. Europe's regulator calls NAION, an eye condition that can cause vision loss, a very rare side effect of semaglutide. Sudden vision loss in one eye is an emergency. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA 2023 (research letter) (https://pmc.ncbi.nlm.nih.gov/articles/PMC10557026/) - PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) ## Will I lose muscle or get "Ozempic face"? Weight loss usually includes some lean mass, but less than fat. All three weight labels, for Wegovy, Zepbound and Foundayo, say fat loss is larger, and body-scan studies of semaglutide and tirzepatide agree. Lean mass isn't only muscle, and strength training plus enough protein may help protect it. 'Ozempic face' isn't a medical term. It's facial fat loss that can follow any fast weight loss, including surgery. Lean mass also includes organs, bone and water, and trials haven't measured strength well. Older adults may face a higher risk of muscle loss. A 2025 nutrition advisory leans on regular strength work, noting that protein alone likely isn't enough without it, and gives about 80 to 120 grams of protein a day as one easy-to-follow target. A clinician or dietitian can set your own number. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Wilding JPH, et al. Impact of Semaglutide on Body Composition in Adults With Overweight or Obesity: Exploratory Analysis of the STEP 1 Study (conference abstract, 2021) (https://www.newswise.com/pdf_docs/16159288255831_Wilding%20Abstract.pdf) - Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight. Diabetes Obes Metab 2025 (abstract via Europe PMC, PMID 39996356) (https://doi.org/10.1111/dom.16275) - Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024 (abstract via Europe PMC, PMID 38937282) (https://doi.org/10.1111/dom.15728) - 'Ozempic Face': What It Is and How to Avoid It (https://health.clevelandclinic.org/ozempic-face) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## Which symptoms need urgent help? If it feels like an emergency, call 911 now. Get care right away for severe belly pain that won't go away, especially if it spreads to your back, for signs of a serious allergic reaction, or for sudden vision loss in one eye. Call your prescriber promptly if you can't keep fluids down, or have upper belly pain, fever, or yellowing skin or eyes. If you're having thoughts of suicide, call or text 988. If pancreatitis is suspected, the labels say to stop the medicine and get care. Also call your prescriber about a lump in your neck, lasting hoarseness, dizziness, or passing very little urine. Tell any surgical team you take one before sedation. You can report a side effect to FDA MedWatch at 1-800-FDA-1088. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) - FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications (Drug Safety Communication) (https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp) - 988 Suicide & Crisis Lifeline (call or text 988, chat online; free, confidential, 24/7) (https://988lifeline.org/) ## How much do these medicines cost? It depends on the medicine, the dose and how you pay. As of September 2026, cash prices straight from Novo Nordisk or Lilly ran from $149 to $699 a month. A private plan that covers it, plus a maker's savings card, can bring it to as little as $25. Eligible Medicare members can pay $50 through a temporary program. List prices are far higher, but most insured people don't pay list. Here's how it broke down as of September 2026. Wegovy, which is semaglutide, was $349 a month cash for the pen, or $199 for the first two starter fills for new patients. Wegovy HD was $399, and the Wegovy pill $149 to $299 by dose. Zepbound, which is tirzepatide, was $299 to $449 for vials or the KwikPen with on-time refills, up to $699 if a refill is late. Foundayo, which is orforglipron, was $149 to $299, or $349 late. Several offers end December 31, 2026. Sources: - Wegovy (semaglutide) Savings, Self Pay, & Home Delivery, NovoCare Pharmacy (https://www.novocare.com/pharmacy/wegovy/offer.html) - Wegovy (semaglutide) Cost, Coverage, & Savings Resources, NovoCare (includes list prices) (https://www.novocare.com/patient/medicines/wegovy.html) - Authentic Zepbound (tirzepatide) Shipped to You, LillyDirect product and self-pay price page (CMAT-05333 08/2026) (https://www.lilly.com/lillydirect/zepbound) - Authentic Foundayo (orforglipron) Shipped to You, LillyDirect product and self-pay price page (CMAT-19155 09/2026) (https://www.lilly.com/lillydirect/foundayo) - Foundayo (orforglipron) Savings & Coverage, including savings card and self-pay terms (CMAT-28773 08/2026) (https://foundayo.lilly.com/hcp/savings-coverage) - Zepbound (tirzepatide) Coverage, Affordability, and Savings, including savings card and KwikPen self-pay terms (consumer page; HCP version at zepbound.lilly.com/hcp/coverage-savings) (https://zepbound.lilly.com/coverage-savings) - Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234) (https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf) - TrumpRx.gov home page (featured GLP-1 prices shown next to an original price) (https://trumprx.gov/) ## Will my insurance cover it? Only your plan can say for sure, but there are patterns. Many job-based plans cover GLP-1s for diabetes but not for weight, and that's usually the employer's choice. Coverage is more common at big employers. When a plan does cover it, it often needs prior authorization first, meaning your prescriber sends proof you meet the plan's rules. One call to the number on your card can settle it. For context, in KFF's 2025 survey 43% of firms with 5,000 or more workers covered GLP-1s for weight, but only 16% of firms with 200 to 999 workers did. A 2026 employer survey found 36% covered them for weight and 60% for diabetes only. If you're denied, ask why, because missing paperwork is often fixable. Plans that follow the Affordable Care Act rules generally give you 180 days to appeal. If weight medicines are excluded by design, an appeal may not change that. Sources: - 2025 Employer Health Benefits Survey (https://www.kff.org/health-costs/2025-employer-health-benefits-survey/) - GLP-1 Drugs Survey Report: What Employers Are and Aren't Covering in 2026 (https://blog.ifebp.org/glp-1-drugs-survey-report-what-employers-are-and-arent-covering-in-2026/) - Internal appeals (https://www.healthcare.gov/appeal-insurance-company-decision/internal-appeals/) - CVS Caremark delivers affordability and access to GLP-1 weight management medications with expanded coverage options (https://www.cvshealth.com/news/company-news/cvs-caremark-delivers-affordability-and-access-to-glp-1-weight-management-medications-with-expanded-coverage-options.html) - Zepbound (tirzepatide) Coverage, Affordability, and Savings, including savings card and KwikPen self-pay terms (consumer page; HCP version at zepbound.lilly.com/hcp/coverage-savings) (https://zepbound.lilly.com/coverage-savings) - Weight Loss Medications FAQs (State of Delaware Group Health Insurance Plan) (https://dhr.delaware.gov/benefits/cvs/documents/weight-management-faq.pdf) ## Does Medicare cover GLP-1s? Not for weight loss under regular Part D, because the law bars it. But Medicare drug plans can cover these medicines for other approved uses, like type 2 diabetes, sleep apnea, heart risk or MASH liver disease. And since July 1, 2026, a temporary program called the Medicare GLP-1 Bridge lets eligible people get Wegovy, Foundayo or the Zepbound KwikPen for weight at $50 a month, as of September 2026. To qualify, you need Medicare drug coverage, can't already get a GLP-1 through your plan, and must meet a BMI rule from when you started: 35 or more, or 30 with certain heart, blood-pressure or kidney conditions, or 27 with prediabetes or a past heart attack, stroke or leg-artery disease. Diabetes, sleep apnea and MASH go through regular Part D instead. The catches: the $50 doesn't count toward your Part D cap, Extra Help doesn't lower it, and there's no formal appeal. It ends December 31, 2027. Sources: - What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge (https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/) - Medicare GLP-1 Bridge: Information for Providers (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers) - Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234) (https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf) - Medicare GLP-1 Bridge: Information for Part D Plans (https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans) - CMS Launches Medicare GLP-1 Bridge, Expanding Access to GLP-1 Medications (https://www.cms.gov/newsroom/press-releases/cms-launches-medicare-glp-1-bridge-expanding-access-glp-1-medications) - CMS decision to remove obesity drug coverage from 2026 final rule disappoints societies (secondary source; Federal Register text not reviewed) (https://www.healio.com/news/endocrinology/20250411/cms-decision-to-remove-obesity-drug-coverage-from-2026-final-rule-disappoints-societies) - Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) (https://www.cms.gov/files/document/fact-sheet-negotiated-prices-ipay-2027.pdf) - What Medicare's Temporary Program Covering GLP-1s for Obesity Means for Beneficiaries (https://kfforg.substack.com/p/what-medicares-temporary-program) ## What are the cheapest legitimate ways to pay? Start with the coverage you have. As of September 2026, a covered private plan plus a savings card could get the cost as low as $25 a month. On Medicare, the Bridge is $50 if you qualify. Without coverage, the makers' own cash prices, also listed on TrumpRx.gov, went from $149 up to $699 by medicine and dose. If you're insured, check your copay before paying cash, because it may be lower. Watch for some traps. Savings cards don't work for anyone with Medicare, Medicaid, TRICARE or VA coverage, and their caps mean a high copay can still leave you paying more than $25. Cash purchases usually don't count toward your deductible. Lilly's lower cash prices on higher doses need each refill within 45 days, or the price can jump by $50 to $250. Some intro prices end December 31, 2026. And a price that seems too good to be true is an FDA red flag, not a bargain. Sources: - Zepbound (tirzepatide) Coverage, Affordability, and Savings, including savings card and KwikPen self-pay terms (consumer page; HCP version at zepbound.lilly.com/hcp/coverage-savings) (https://zepbound.lilly.com/coverage-savings) - Foundayo (orforglipron) Savings & Coverage, including savings card and self-pay terms (CMAT-28773 08/2026) (https://foundayo.lilly.com/hcp/savings-coverage) - Wegovy (semaglutide) Savings, Self Pay, & Home Delivery, NovoCare Pharmacy (https://www.novocare.com/pharmacy/wegovy/offer.html) - Medicare GLP-1 Bridge: GLP-1 Drugs for $50 a Month (CMS Product No. 12234) (https://www.medicare.gov/publications/12234-medicare-glp-1-bridge-glp-1-drugs-for-50-a-month.pdf) - Wegovy Pen on TrumpRx (offer terms and eligibility) (https://trumprx.gov/p/wegovy) - TrumpRx.gov home page (featured GLP-1 prices shown next to an original price) (https://trumprx.gov/) - Authentic Zepbound (tirzepatide) Shipped to You, LillyDirect product and self-pay price page (CMAT-05333 08/2026) (https://www.lilly.com/lillydirect/zepbound) - Authentic Foundayo (orforglipron) Shipped to You, LillyDirect product and self-pay price page (CMAT-19155 09/2026) (https://www.lilly.com/lillydirect/foundayo) - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) ## Are compounded or online versions safe? They aren't checked the way approved medicines are. Compounded semaglutide and tirzepatide are not FDA-approved, and the FDA doesn't review them for safety, quality or effectiveness before sale. They aren't generics either. As of May 31, 2026, the FDA had 990 adverse event reports tied to compounded semaglutide and more than 730 tied to compounded tirzepatide. Some people ended up in hospital after dosing mistakes. Since the shortages ended in 2024 and 2025, the FDA says large outsourcing facilities can't compound these from bulk ingredients, and pharmacies can't routinely make copies of approved drugs. It has sent warning letters to telehealth companies claiming their products are the same as approved drugs. Fake Ozempic pens have also turned up in the US supply chain. If you're using a compounded product now, it's okay to tell your clinician or pharmacist. It helps them keep you safe. Sources: - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) - FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (https://www.fda.gov/drugs/drug-alerts-and-statements/fda-clarifies-policies-compounders-national-glp-1-supply-begins-stabilize) - FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (https://www.fda.gov/news-events/press-announcements/fda-intends-take-action-against-non-fda-approved-glp-1-drugs) - FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1s) - FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain (https://www.fda.gov/drugs/drug-alerts-and-statements/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain) - FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (content current as of 09/01/2026) (https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) ## What should I eat on a GLP-1? Smaller meals, built around protein and whole foods. That's the core of a 2025 advisory from four obesity and nutrition groups. Big meals make vomiting more likely, so eat less at a time, especially early on. Fill plates with vegetables, fruit, whole grains, beans and lean protein, and eat the protein first. Sip fluids through the day. A registered dietitian can tailor this to you. Protein matters because when appetite drops, it's easy to eat too little of it. The advisory mentions a simple target of about 80 to 120 grams a day, though experts haven't agreed on an exact number, and people with kidney disease may need a different one. In the first days, going easy on fatty and high-fiber foods can ease nausea. It also suggests limiting sugary drinks, refined carbs, and red and processed meats. Heavy hair loss, unusual tiredness or slow healing are worth mentioning to a clinician. Sources: - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## Can I still drink alcohol? There's no set alcohol limit on the Wegovy, Zepbound or Foundayo labels. But a 2025 nutrition advisory says to keep it to a minimum, because alcohol can worsen nausea and reflux on these medicines. It can also add to fluid loss, and all three labels warn about kidney injury from dehydration. If you take insulin or a sulfonylurea, ask a clinician first, since low blood sugar is more likely with that mix. Many people say drinks hit harder or feel less appealing on these medicines. That's a personal report, not a proven effect. Researchers are also studying whether semaglutide reduces drinking. In a 2026 Danish trial of 108 adults with alcohol use disorder and obesity, heavy drinking days fell more with semaglutide plus therapy than with placebo plus therapy. It was small and partly funded by the Novo Nordisk Foundation, and none of these medicines is approved to treat drinking. If drinking worries you, a clinician can talk through proven treatments. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Klausen MK, et al. Once-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial. Lancet 2026. Publisher page blocked (HTTP 403); abstract verified via Europe PMC (PMID 42070571); press-release figures from EurekAlert! (Apr 30, 2026) (https://doi.org/10.1016/S0140-6736(26)00305-3) ## How do I handle dinners, holidays and dates? A few bites and a short line usually do it. Many people feel full quickly, so they order an appetizer as a meal, share plates, or box up leftovers. "I had a big lunch" covers most tables. At holidays, some people talk to the host first. On a date, whether you mention the medicine is your call, like any health detail. Going easy on big, rich meals and alcohol can help with nausea. Practical moves help. Eat the protein on your plate first, keep portions small, and pass on seconds without apology. If you're asked why you're not drinking, "I'm taking it easy tonight" is enough. Studies in 2026 found people rated a fictional person less kindly when a GLP-1 medicine, rather than diet and exercise, was behind the weight loss. So keeping the medicine to yourself at the table is a reasonable choice. Others tell one trusted person at the gathering, so it feels easier. Sources: - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. Int J Obes 2026;50(7):1478-1485 (online Apr 3, 2026). doi:10.1038/s41366-026-02061-y (https://pmc.ncbi.nlm.nih.gov/articles/PMC13391369/) - Post SM, Stock ML, Persky S. Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity. Stigma and Health 2026. doi:10.1037/sah0000689 (https://pmc.ncbi.nlm.nih.gov/articles/PMC13196875/) ## Do I still need to exercise? Yes, and for a specific reason. Some of the weight lost on any weight-loss treatment is lean mass, which includes muscle. A 2025 nutrition advisory recommends strength training at least three times a week plus at least 150 minutes a week of moderate activity like brisk walking, and says protein alone likely won't protect muscle. Each weight label, from Wegovy to Foundayo, also asks for more activity alongside the medicine. In the STEP 1 trial of Wegovy-dose semaglutide, about 38% of the weight lost was lean mass, and the advisory estimates roughly half of that was muscle. Experts still debate how much it matters for strength. A trial with liraglutide, an older daily GLP-1, found exercise plus the medicine cut body-fat percentage about twice as much as either alone. Strength work doesn't need a gym. Body weight, bands and household weights count. With heart or joint limits, check with a clinician first. Sources: - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Lundgren JR, et al. Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. N Engl J Med 2021;384:1719-1730 (https://doi.org/10.1056/NEJMoa2028198) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## What about travel, storage and missed doses? Injections need the fridge, pills don't. Wegovy and Zepbound injections must never freeze, and each allows a limited number of days out of the fridge. Wegovy and Foundayo tablets stay at room temperature. Keep medicine in your carry-on and tell the TSA officer about liquid medicine at the checkpoint. Missed-dose rules differ by medicine, so check your label or ask your pharmacist rather than guess. A Wegovy single-dose pen can sit at 46 to 86 degrees Fahrenheit for up to 28 days before the cap comes off. A Zepbound single-dose pen or vial gets up to 21 days total at up to 86 degrees. Miss a Wegovy shot? Take it if your next dose is more than 2 days away. For Zepbound, within 4 days. For Foundayo, as soon as you can, never doubling up. A missed Wegovy tablet is simply skipped. Hot cars and checked bags can push pens past their limits. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - What Can I Bring? Medications (Liquid) (https://www.tsa.gov/travel/security-screening/whatcanibring/items/medications-liquid) - What Can I Bring? Gel Ice Packs (https://www.tsa.gov/travel/security-screening/whatcanibring/items/gel-ice-packs) - I am traveling with medication, are there any requirements I should be aware of? (FAQ) (https://www.tsa.gov/travel/frequently-asked-questions/i-am-traveling-medication-are-there-any-requirements-i-should-be) - CDC Yellow Book: Traveling with Prohibited or Restricted Medications (https://www.cdc.gov/yellow-book/hcp/travelers-with-additional-considerations/traveling-with-prohibited-or-restricted-medications.html) ## What if my partner or family doesn't approve? You don't owe anyone a defense of your medical care. It still helps to know what's behind the pushback. Often it's worry, old beliefs about willpower, or something seen online. Some people share one plain fact, like the body fighting weight loss through hunger hormones. Others simply say it's between them and their doctor. If the worry is about safety, inviting them to a visit can turn fear into shared understanding. Evidence alone may not change their view. In 2025 studies with 640 US adults, reading about how well these medicines work didn't change how people viewed obesity. Their views tracked beliefs about willpower. So a clear boundary may do more than a debate. If a partner worries about side effects, that's fair, because the risks are real. Reading the official label together gives you both the same facts. The decision itself stays with you and your clinician. Sources: - Goldkorn M, Schwartz B, Monterosso J. Views Among the General Public on New Anti-Obesity Medications and on the Perception of Obesity as a Failure of Willpower. Obes Sci Pract 2025;11(2):e70041 (two online studies, N=640 total) (https://pmc.ncbi.nlm.nih.gov/articles/PMC12012989/) - Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med 2011;365:1597-1604 (https://www.nejm.org/doi/full/10.1056/NEJMoa1105816) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) ## Will it change my relationship with food? Many people find it does. Studies summed up in a 2025 nutrition advisory show less preoccupation with food, less emotional eating and fewer binge episodes on these medicines. Many people describe it as quieter food noise. It isn't always simple, though. Nausea can bring on cravings for comfort food, some people go off certain foods, and losing food as a comfort can feel strange. Food can be comfort, routine and time with people, not just fuel, so the change can feel like a loss even when the quiet is welcome. A registered dietitian can help you eat enough, and a therapist can help if food was how you coped. The research on food noise is young, and in one person tracked with brain recordings, food thoughts returned after months on tirzepatide. Sources: - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Dhurandhar EJ, et al. Food noise: definition, measurement, and future research directions. Nutr Diabetes 2025;15:30 (abstract via Europe PMC, PMID 40628707) (https://doi.org/10.1038/s41387-025-00382-x) - Her food cravings vanished on Mounjaro then roared back (news summary of a University of Pennsylvania Nature Medicine study with implanted brain electrodes in four people with obesity and loss-of-control eating, focused on one participant; secondary source) (https://www.sciencedaily.com/releases/2025/12/251208052534.htm) - Diktas HE, et al. Development and validation of the Food Noise Questionnaire. Obesity 2025;33(2):289-297 (abstract via Europe PMC, PMID 39828656) (https://doi.org/10.1002/oby.24216) ## Can it affect my mood? The biggest fear hasn't held up. In January 2026 the FDA reviewed 91 trials with nearly 108,000 people, found no increased risk of suicidal thoughts or depression, and asked for that warning to come off the Wegovy and Zepbound labels. Some people still describe emotional shifts, like missing food as a comfort. Tell a clinician about new or worsening low mood. If you ever think of suicide, call or text 988 in the US. Europe's medicines regulator reached a similar view in April 2024. The Foundayo label, first approved in 2026, doesn't carry that warning. What people do describe is quieter: feeling unsure who they are as their body changes, or losing a way of coping. A 2025 nutrition advisory recommends stress management, cognitive behavioral therapy when it helps, and good social connection as part of care. Weight stigma itself is linked with depression and anxiety. Sources: - FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications (Drug Safety Communication) (https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp) - Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024 (GLP-1 receptor agonists and suicidal thoughts; page loaded directly 2026-09-23) (https://www.ema.europa.eu/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x (endorsing organizations listed as of Feb 26, 2020) (https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/) - 988 Suicide & Crisis Lifeline (call or text 988, chat online; free, confidential, 24/7) (https://988lifeline.org/) ## What if people treat me differently after I lose weight? Some will, and it can feel strange either way. A common experience is praise that feels like your old body was never acceptable, or still seeing your old self in the mirror. A 2026 online experiment found people were less keen to spend time with someone who lost weight using a GLP-1 than through diet and exercise. How much you explain is up to you, and a therapist who works with body image can help. Keep that research in proportion. It used made-up people in online experiments, so it shows attitudes, not what anyone will actually do. A second 2026 study found overall attitudes were still neutral or leaning positive. Physical changes can draw comments too, like a thinner face. Ozempic face is a media phrase, not a medical term, and the same change can follow weight loss by any route. How you lost weight is your story to tell, or not. Sources: - Standen EC, Phelan SM, Tomiyama AJ. An experimental investigation of the stigmatization of weight loss and regain from GLP-1 receptor agonist use and cessation. Int J Obes 2026;50(7):1478-1485 (online Apr 3, 2026). doi:10.1038/s41366-026-02061-y (https://pmc.ncbi.nlm.nih.gov/articles/PMC13391369/) - Post SM, Stock ML, Persky S. Social Perceptions of Weight Loss With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Black and White Women With Obesity. Stigma and Health 2026. doi:10.1037/sah0000689 (https://pmc.ncbi.nlm.nih.gov/articles/PMC13196875/) - Daneshgaran G, Shauly O, Gould DJ. "Ozempic Face" in Plastic Surgery: A Systematic Review of the Literature on GLP-1 Receptor Agonist Mediated Weight Loss and Analysis of Public Perceptions. Aesthet Surg J Open Forum 2025;7:ojaf056 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12232544/) - 'Ozempic Face': What It Is and How to Avoid It (https://health.clevelandclinic.org/ozempic-face) ## How do I bring this up with my doctor without feeling judged? Say it plainly: "I'd like to talk about whether a weight medicine could be right for me." A US health institute, the NIDDK, calls talking about weight with a professional an important first step. Bring what you've tried, your health conditions and all your medicines. You can ask to be weighed privately, or not told the number. Feeling judged by doctors is well documented, and it's fair to find someone who treats you with respect. The NIDDK suggests asking how your weight is affecting your health, and whether losing weight would help specific problems you have. Mention any history of eating disorders, any pregnancy plans, and whether cost is a worry. If it helps, say, "I've had bad experiences talking about weight. Can we go slowly?" A clinician may say no or not yet, and you can ask them to explain why. Obesity medicine specialists are listed in the ABOM and OMA directories. Sources: - Choosing a Safe & Successful Weight-loss Program (last reviewed Feb 2024) (https://www.niddk.nih.gov/health-information/weight-management/choosing-a-safe-successful-weight-loss-program) - Puhl RM. Weight Stigma and Barriers to Effective Obesity Care. Gastroenterol Clin N Am 2023;52:417-428. doi:10.1016/j.gtc.2023.02.002 (https://uconnruddcenter.org/wp-content/uploads/sites/2909/2023/05/2023-Puhl-Gastroeneterol-Clin-N-Am.pdf) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) - ABOM Diplomate Search and Certification Verification (public search by name, city and state or province) (https://abom.learningbuilder.com/Search/Public/MemberRole/CertificationVerification) - Find an Obesity Doctor Near You (provider directory) (https://obesitymedicine.org/about/find-a-provider/) ## Isn't this just big pharma selling a quick fix? It's not a quick fix, but the skepticism is fair. Novo Nordisk and Eli Lilly paid for most of the big trials, and I'll tell you when they did. The medicines are meant to sit on top of diet and activity, not replace them. In trials, people who stopped semaglutide (Wegovy) or tirzepatide (Zepbound) regained much of the weight within a year, so for many it's long-term treatment. The science is older than the hype. Researchers found GLP-1 in the 1980s, and the first GLP-1 medicine, exenatide (Byetta), was approved for diabetes in 2005. Independent work counts too. A 2026 review in The BMJ, funded in part by the UK's national health research institute, found weight returns after stopping, faster for semaglutide and tirzepatide. Skepticism and interest can both be reasonable, and a clinician who knows your health can weigh them with you. Sources: - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - Wharton S et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025;393:1796-1806. doi:10.1056/NEJMoa2511774 (https://pubmed.ncbi.nlm.nih.gov/40960239/) - Aronne LJ, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2416394) - Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab 2022;24(8):1553-1564 (https://pmc.ncbi.nlm.nih.gov/articles/PMC9542252/) - Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA 2024;331(1):38-48. doi:10.1001/jama.2023.24945 (https://pmc.ncbi.nlm.nih.gov/articles/PMC10714284/) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 2026 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/) - 2024 Lasker~DeBakey Clinical Medical Research Award: GLP-1-based therapy for obesity (Habener, Mojsov, Knudsen) (https://laskerfoundation.org/winners/glp-1-based-therapy-for-obesity/) - Drugs@FDA original (ORIG-1) approval records for Byetta, Victoza, Saxenda, Ozempic, Rybelsus, Wegovy, Wegovy tablets, Mounjaro, Zepbound and Foundayo, and the NDA 213051 product list (Rybelsus and Ozempic semaglutide tablets), queried through the openFDA drugsfda API (https://www.accessdata.fda.gov/scripts/cder/daf/) ## What don't we know yet about long-term use? Quite a lot, honestly. GLP-1 medicines have treated diabetes in the US since 2005, but at weight-loss doses in people without diabetes, the longest large trials run about four years. Nobody knows yet what decades of use do, or starting in the teen years. It's also unclear whether rare risks like thyroid cancer appear only later, and how best to stop or taper. Unknown doesn't mean harmful. It means we don't know yet. The longest big trial at weight doses is SELECT, which followed people on semaglutide (Wegovy) for about 40 months on average. Tirzepatide (Zepbound) weight data run about 3.4 years, and orforglipron (Foundayo) was approved on 72-week trials. The largest thyroid cancer study so far averaged 3.9 years. Trials haven't measured muscle strength well, and data on regain after stopping run only about a year. Pregnancy data are thin too, and the Wegovy label says to stop at least 2 months before a planned pregnancy. Sources: - Drugs@FDA original (ORIG-1) approval records for Byetta, Victoza, Saxenda, Ozempic, Rybelsus, Wegovy, Wegovy tablets, Mounjaro, Zepbound and Foundayo, and the NDA 213051 product list (Rybelsus and Ozempic semaglutide tablets), queried through the openFDA drugsfda API (https://www.accessdata.fda.gov/scripts/cder/daf/) - Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med 2023;389(24). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2307563) - Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nat Med 2024 (https://doi.org/10.1038/s41591-024-02996-7) - Jastreboff AM et al. Tirzepatide for Obesity Treatment and Diabetes Prevention (SURMOUNT-1, 176 weeks). N Engl J Med 2025;392(10):958-971. doi:10.1056/NEJMoa2410819 (https://pubmed.ncbi.nlm.nih.gov/39536238/) - Wharton S, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). N Engl J Med 2025 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2511774) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - Pasternak B, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 2024 (https://doi.org/10.1136/bmj-2023-078225) - West S, et al. Weight regain after cessation of medication for weight management: systematic review and meta-analysis. BMJ 2026 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12776922/) - Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. Diabetes Obes Metab 2024 (abstract via Europe PMC, PMID 38937282) (https://doi.org/10.1111/dom.15728) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - Almaradweh S, Mousa E. Glucagon-Like Peptide-1 Receptor Agonists and Reproductive Health: A Narrative Review for Obstetrician-Gynecologists. Cureus 2026;18(7):e111915 (narrative review; secondary source) (https://pmc.ncbi.nlm.nih.gov/articles/PMC13428985/) ## Shouldn't diet and exercise be enough? They're the foundation either way, and every weight label builds on them. For many people, though, they aren't enough on their own, because biology pushes back after weight loss. In one study, the hunger hormone ghrelin stayed higher a year later. Twin and family studies suggest genes account for 40 to 70% of weight differences between people. Finding it hard isn't a character flaw. That 2011 study followed 50 people after a very-low-calorie diet. A year on, ghrelin was still higher, several fullness hormones were lower, and they felt hungrier. Many clinicians compare a weight medicine to one for blood pressure or cholesterol. The American Medical Association has called obesity a disease since 2013, though not every expert agrees. Strength training and good food still matter on medicine. If a medicine interests you, bring it to a clinician, who can judge whether and when it makes sense. Sources: - Sumithran P, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med 2011;365:1597-1604 (https://www.nejm.org/doi/full/10.1056/NEJMoa1105816) - Loos RJF, Yeo GSH. The genetics of obesity: from discovery to biology. Nat Rev Genet 2022;23(2):120-133 (online Sep 2021). doi:10.1038/s41576-021-00414-z (https://pmc.ncbi.nlm.nih.gov/articles/PMC8459824/) - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - AMA Policy H-440.842, Recognition of Obesity as a Disease (adopted June 2013, Resolution 420 A-13) (https://policysearch.ama-assn.org/policyfinder/detail/H-440.842?uri=/AMADoc/HOD.xml-0-3858.xml) - Rubino F, Puhl RM, Cummings DE, et al. Joint international consensus statement for ending stigma of obesity. Nat Med 2020;26(4):485-497. doi:10.1038/s41591-020-0803-x (endorsing organizations listed as of Feb 26, 2020) (https://pmc.ncbi.nlm.nih.gov/articles/PMC7154011/) - Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from ACLM, ASN, OMA and The Obesity Society. Obesity Pillars 2025 (also in Am J Clin Nutr, Am J Lifestyle Med, Obesity). doi:10.1016/j.obpill.2025.100181 (https://pmc.ncbi.nlm.nih.gov/articles/PMC12264624/) ## Where does your information come from? Are you paid by drug companies? From public sources you can check: FDA prescribing labels and safety notices, trials published in journals like The New England Journal of Medicine and The Lancet, Europe's medicines regulator, and groups like KFF. Every number carries a date. I'm designed not to favour any brand. When a trial was paid for by the company that makes the medicine, I say so. Most of the big ones were. Prices and rules change fast, so I tell you when a number was true. Where evidence is thin or disputed, I say so. Where a figure comes from a company press release rather than a peer-reviewed paper, I say that too. I'm not a clinician. For anything about your own dose or health, your prescriber or pharmacist is the right check. Sources: - WEGOVY (semaglutide) injection and tablets, US Prescribing Information and Medication Guide (Revised 06/2026) (https://www.novo-pi.com/wegovy.pdf) - ZEPBOUND (tirzepatide) injection, US Prescribing Information (Revised 08/2026) (https://pi.lilly.com/us/zepbound-uspi.pdf) - FOUNDAYO (orforglipron) tablets, US Prescribing Information (Revised 7/2026; initial US approval 2026) (https://uspl.lilly.com/foundayo/foundayo.html) - FDA Requests Removal of Suicidal Behavior and Ideation Warning from GLP-1 Receptor Agonist Medications (Drug Safety Communication) (https://www.fda.gov/drugs/drug-safety-communications/fda-requests-removal-suicidal-behavior-and-ideation-warning-glucagon-peptide-1-receptor-agonist-glp) - Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med 2021;384(11). Abstract via Europe PMC (https://doi.org/10.1056/NEJMoa2032183) - Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med 2022 (abstract via Europe PMC) (https://doi.org/10.1056/NEJMoa2206038) - PRAC concludes eye condition NAION is a very rare side effect of semaglutide medicines Ozempic, Rybelsus and Wegovy (https://www.ema.europa.eu/en/news/prac-concludes-eye-condition-naion-very-rare-side-effect-semaglutide-medicines-ozempic-rybelsus-wegovy) - Poll: 1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug for Weight Loss, Diabetes or Another Condition, Even as Half Say the Drugs Are Difficult to Afford (https://www.kff.org/public-opinion/poll-1-in-8-adults-say-they-are-currently-taking-a-glp-1-drug-for-weight-loss-diabetes-or-another-condition-even-as-half-say-the-drugs-are-difficult-to-afford/) ## Are you human, and what do you remember about me? No, I'm Nori, an AI built by Mobeus. My face appears in short explainer videos, but I'm not a person. On this device, I remember a short summary of our past conversations and things you chose to share. Ask me to forget, and I'll forget everything. I can't book appointments, prescribe, check your insurance, or connect you to a human. I'm not a clinician either. I remember things on this device so you don't have to repeat yourself. If you share something and later wish you hadn't, just say so and I'll forget it all. For anything that needs a person, like booking a visit or checking coverage, your clinician's office, pharmacist or insurer can help, and I can help you get your questions ready first.